Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells

Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels

(2012) Asli Kisim et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts

(2011) Joseph A Rakowski et al.   Expert Review of Anticancer Therapy

Proapoptotic Protein Smac Mediates Apoptosis in Cisplatin-resistant Ovarian Cancer Cells When Treated with the Anti-tumor Agent AT101

(2011) Wenbin Hu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer

(2011) Neal Ready et al.   Journal of Thoracic Oncology

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins

(2011) Anton Stangelberger et al.   PROSTATE

Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience

(2010) Rachel F DEAR et al.   Asia-Pacific Journal of Clinical Oncology

Epigenetics of ovarian cancer: From the lab to the clinic

(2010) Reza Asadollahi et al.   GYNECOLOGIC ONCOLOGY

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

(2010) Thomas J. Herzog et al.   GYNECOLOGIC ONCOLOGY

Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer

(2010) Rebecca Suk Heist et al.   Journal of Thoracic Oncology

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer

(2010) Luigi Moretti et al.   Journal of Thoracic Oncology

Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer

(2010) Constanze Zeller et al.   Therapeutic Advances in Medical Oncology

Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide

(2009) Cigdem Erten et al.   BJU INTERNATIONAL

Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination

(2009) U SANLI   CELL BIOLOGY INTERNATIONAL

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

(2009) G. Liu et al.   CLINICAL CANCER RESEARCH

Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib

(2009) Henk J. Broxterman et al.   DRUG RESISTANCE UPDATES

Minireview: Epigenetic Changes in Ovarian Cancer

(2009) Curt Balch et al.   ENDOCRINOLOGY

Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination

(2009) Ercument Cengiz et al.   MOLECULAR BIOLOGY REPORTS

AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis

(2009) Shuraila F Zerp et al.   Radiation Oncology

Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells

(2008) Huei-Fang Liu et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Cysteine 62 of Bax Is Critical for Its Conformational Activation and Its Proapoptotic Activity in Response to H2O2-induced Apoptosis

(2008) Chunlai Nie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY